logo
Salud por Derecho
Eng
  • Esp
  • Eng
logo
  • ABOUT US
  • WHAT WE DO
  • COLLABORATE
  • NEWS
Imagen destacada
Home Slider
7.4 billion euros for vaccines and COVID-19 treatments… but is it enough?
07/05/2020 by Salud in Home Slider

Last Monday saw the online Global Coronavirus Response conference – organised and led by the European Commission President – at which civil, philanthropic and private sector organisations from around the world donated 7.4 billion euros to accelerate research and development work for COVID-19 testing, drugs and vaccines.

This initiative was in response to the World Health Organisation and other global health actors’ call for the global coronavirus crisis to be addressed. It included an important principle – namely, that any medicines, vaccines and other tools developed should be made available to everyone who needs them, at affordable prices, and without leaving anyone out.

This initiative is great news and we welcome it.

However, as other organisations have already warned, this brings up many questions about a number of important issues. For example, how will global access to any COVID-19 treatments, vaccines and tools that emerge from this research be ensured? How will global production and supply be ensured for all countries – without distinction and when they need it? Who will own the intellectual property for the treatments and vaccines? How will prices be set? By whom? How will open access to the knowledge generated under the research be ensured? What accountability and transparency mechanisms will be put in place?

Raising large sums of money is not enough. To ensure that drugs, vaccines and other tools reach everyone around the world, donor governments need to attach specific rules and conditions to the contributions they make and to any agreements with public and private actors who receive such funding, in order that any products developed are truly considered and treated as global public assets.

Agreements that give governments the ability to set the prices for these products. Fair and affordable prices, based on the actual costs of the research and the amount of public investment, and taking into account a reasonable profit margin for any research groups or companies that develop them.

This is the only way that national health systems in all countries – rich or poor – will be able to afford them and reach everyone who needs them, at no cost, with priority to the most vulnerable and those most at risk.

Under their terms and conditions, governments should impose agreements with any research groups, private companies or other R&D players that receive part of these public funds (which have gone mainly to multilateral bodies like CEPI and GAVI). Any vaccines, treatments or diagnostic tools that are developed should not be under exclusive licenses, to avoid monopolies and to make it easier for several producers to manufacture and distribute them to meet one of the great challenges of this pandemic: to produce sufficient quantities to supply the needs of all countries.

In addition, conditions should be attached so that any data obtained, knowledge generated and results from the different phases of the research are put into the public domain and openly shared with the scientific community. This will speed up other research and help reduce related costs and the final prices of future treatments and vaccines.

There is also, of course, a need for global, inclusive and transparent governance, with open doors and accountability systems so that the scope of actions is known, along with how and where public funds have been or will be invested, to monitor progress and understand which agreements have been reached and which actors are involved. Furthermore, this governance should include organisations from civil society.

The Global Coronavirus Response initiative is just getting started, and this round of fundraising is only the first phase. It is nevertheless great news. Last Monday we saw the leaders of countries including France, Japan, Canada, Italy and Spain – which put in 125 million euros, similar to the 100 million euros committed last year to the Global Fund to Fight AIDS, Tuberculosis and Malaria – speak openly about their commitment to R&D for drugs and vaccines and ensuring global access to them.

However, there are still many steps to be taken and many questions to be answered in order to see how that commitment will materialise, so that no one is left behind in the fight against this pandemic.

Compartir:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
Linkedin
Share on email
Email
Share on whatsapp
Whatsapp
Salud

Search

Subscribe to Newsletter

Estoy de acuerdo con la Política de privacidad.

LOCATION

Salud por Derecho
Duque Fernán Núñez, 2.
28012 Madrid
saludporderecho@saludporderecho.org

facebook twitter youtube

ABOUT US

About us

What we do

Collaborate

News

Privacy Policy

Cookie Policy

Publications

Press Area

SUBSCRIBE TO OUR NEWSLETTER

Estoy de acuerdo con la Política de privacidad.

Compartir:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
Linkedin
Share on email
Email
Share on whatsapp
Whatsapp
logo
Política de Cookies
Esta web utiliza cookies propias y de terceros para analizar tu navegación y ofrecerte un servicio más personalizado acorde a tus intereses. Continuar navegando implica la aceptación de nuestra Política de Cookies. También hemos actualizado nuestra Política de Privacidad para adecuarnos a la nueva normativa europea, puedes consultarla en la web. Aceptar Rechazar
Política de Cookies

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT